GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » EV-to-FCF

Regenicin (Regenicin) EV-to-FCF : 16.00 (As of May. 24, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Regenicin EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Regenicin's Enterprise Value is $-11.20 Mil. Regenicin's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.70 Mil. Therefore, Regenicin's EV-to-FCF for today is 16.00.

The historical rank and industry rank for Regenicin's EV-to-FCF or its related term are showing as below:

RGIN's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 9.77
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Regenicin's stock price is $0.0001. Regenicin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.006. Therefore, Regenicin's PE Ratio for today is At Loss.


Regenicin EV-to-FCF Historical Data

The historical data trend for Regenicin's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin EV-to-FCF Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.16 -12.61 -19.65 -152.86 -41.49

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.52 -77.24 -41.49 29.22 15.71

Competitive Comparison of Regenicin's EV-to-FCF

For the Biotechnology subindustry, Regenicin's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenicin's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Regenicin's EV-to-FCF falls into.



Regenicin EV-to-FCF Calculation

Regenicin's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-11.200/-0.7
=16.00

Regenicin's current Enterprise Value is $-11.20 Mil.
Regenicin's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenicin  (OTCPK:RGIN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Regenicin's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-0.006
=At Loss

Regenicin's share price for today is $0.0001.
Regenicin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.006.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Regenicin EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Regenicin's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenicin (Regenicin) Business Description

Traded in Other Exchanges
N/A
Address
10 High Court, Little Falls, NJ, USA, 07424
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines